login bet 999

login bet 999 Eli Lilly Zepbound More Effective Than Novo’s Wegovy, Study Finds. Lilly Stock Gains. - Barron's(The Center Square) – Legislators in Washington, D.C., have taken a number of steps over the past few days to push for insurance and pharmaceutical reforms to be passed before the end of the year. On Wednesday, a bicameral group of Republican and Democrat lawmakers held a press conference discussing the need for pharmacy benefit manager reform to protect small pharmacies across the country and “save lives.” “Whether you are a Republican, Democrat, or an independent, we all want the same thing. We want accessible, affordable, quality health care,” said Rep. Buddy Carter, R-Ga. “We’re not here today to just discuss one bill or to discuss just one patient’s story. We're here because there's broad, bipartisan pharmacy benefit manager, or PBM, reform that is needed to save lives.” Pharmacy benefit managers are the middlemen responsible for managing the drug prices covered by health insurance plans. According to the Harvard Political Review , the problem with pharmacy benefit managers is that they “have vertically integrated with pharmacy chains and health insurers through massive conglomerates.” That then allows them to abuse their power to cut out small pharmacies and increase prices. Carter also signed a letter that was released last week calling on the Department of Justice to dig into the role pharmacy benefit managers played in the opioid epidemic. Reps. Raja Krishnamoorthi, D-Ill., Deborah Ross, D-N.C., and Cliff Benz, R-Ore., all joined him in signing that letter. “The opioid crisis has devastated communities in North Carolina and across the country, and PBMs may have fueled it by prioritizing profits over people,” Ross said on social media . “That’s why I joined a letter calling on the DOJ to investigate their role and hold these bad actors accountable.” The letter looked at recent reports on the largest pharmacy benefit managers, CVS Caremark, Express Scripts, and OptumRx which state that they “colluded and conspired to steer patients towards OxyContin in exchange for $400 million.” OxyContin is a trade name for the narcotic oxycodone hydrochloride, a painkiller available by prescription only. This and the general “lack of transparency” is just one of the many complaints that legislators aired on Wednesday. “My colleagues who are joining me today, Democrats and Republicans ... all recognize that PBMs are decreasing the accessibility, the affordability, and therefore the quality of health care in America,” Carter said. “We have an opportunity, right now, to advance bipartisan legislation that increases reporting requirements, which would heighten transparency and shine a light on the opaque practices of these PBMs.” Carter was also joined by Sen. James Lankford, R-Okla., who is leading the effort to get legislation passed in the U.S. Senate. “This year, we're losing about one pharmacy a day in America,” Lankford said. “We want leadership to be able to take this up and to bring it up in the end-of-year package ... Stop holding up legislation that is bipartisan, bicameral, and solving a problem that Americans need solved.”None

NoneHead of Canada’s diplomatic service holds interference briefing for foreign diplomats

Tisdale Curling Club recieves boost in fundingWhile it has a global fanbase that spans age, gender, race, religion and language, “ ” isn’t exactly the most diverse and inclusive universe. Yes, there are Black characters in the books, but they didn’t get much screen time in the movies. It appears that may change with the upcoming “Harry Potter” TV series. According to , “Gangs of London” and “Black Mirror” actor Paapa Essiedu is reportedly in talks to take on the popular role of Professor Severus Snape. Snape is a deeply complicated character who seems to have complex feelings for Harry. He’s one of the most popular characters in the universe, with fans constantly debating whether he’s a hero or a villain. When HBO announced it was doing a new “Harry Potter” series that would incorporate more details from the books, other than Harry, Ron and Hermione, this was destined to be the most controversial casting. In the films, the Alan Rickman delivered an unforgettable performance as Snape. Honestly, no actor can truly follow in his footsteps. In response to someone acknowledging how difficult it will be to follow Rickman’s iconic role, , “Best way to look at it is accept it’ll be different. If the baseline is they won’t be as good as the guy we hold in extremely high regard for the role then it’s an impossible task to live up to but it shouldn’t disqualify the role ever appearing again for other actors.” Best way to look at it is accept it'll be different. If the baseline is they won't be as good as... Of course, that wasn’t a lot of fans’ major issue with Essiedu’s possible casting. Many people weren’t happy about a Black actor taking on a role that is described in the book as “a thin man with sallow skin, a large, hooked nose, and yellow, uneven teeth... shoulder-length, greasy black hair.” Before we get to the intense social media reactions from the Wizarding World, we need to take a moment to discuss how good Essiedu will actually be in this role. The British actor excels at nuanced portrayals of complex, layered characters. When you don’t know how you’re supposed to feel about someone, he adds an emotional depth that instantly captivates audiences. He would be a fantastic Snape. However, on social media, some fans just couldn’t get past his race and see the possibilities for the character. One user is done with all changes to their favorite material, , “I don’t do race swaps. No f***ing thanks. I’m f***ing tired of it.” Since we can’t possibly be good enough to get major opportunities, the DEI haters had to make themselves known with someone , “Same old same old. Everyone, even the ones who will argue with you, KNOWS that he won’t be chosen for his ability to embody the character of Snape. If he’s chosen, it’s because he’s black and they’re frightened to death of not doing so. That’s it. It’s really that simple. Any denial of that fact is willful stupidity.” Another person noted how Snape’s race doesn’t play a role in the story, so this shouldn’t be an issue, , “My thoughts are: race/color has no bearing in the story in any way. He’s a teacher and at no point in the books he being white was important. So, you’re just being racists.” One fan pointed out the obvious on , writing, “Snape is not real lol stop pretending it needs to be accurate when that man is a fictional character.” Someone replied with their opinion that Snape’s original description should be considered, , “He’s a fictional character that has been widely described in books and was casted in the movie series just fine. Just because it’s 2024 doesn’t mean everything has to be “woke” and change up characteristics.” He’s a fictional character that has been widely described in books and was casted in the movie... Another user showed sympathy for the ridiculous level of online attacks the actor will deal with, , “Love Paapa Essiedu but man the harassment this man is about to receive is no where near worth the pay to do a Harry Potter reboot series.” Other than not being able to handle the idea of a Black Snape, there is no reason for Essiedu to not get serious consideration for this role. And by the way, if you’re one of these “Harry Potter” fans saying you won’t watch if this happens, stop wasting our time. That’s not how nerds work. We cannot help ourselves and will absolutely watch all our favorites, no matter how much we may not want to.BOLOGNA, Italy (Reuters) -Jhon Lucumi scored Bologna’s first goal of the Champions League but they fell to a 2-1 home defeat by Lille on Wednesday, with Ngal’ayel Mukau netting twice for the visitors. Lille, who have beaten Real Madrid and Atletico Madrid and drawn with Juventus, are 12th in the standings on 10 points while Bologna are 33rd on one point after slumping to a third successive defeat. Mukau opened the scoring for Lille a minute before the break before Bologna struck through Lucumi in the 63rd minute. The home fans were still celebrating when Mukau scored his second three minutes later and Bologna were unable to find another goal. Bologna came into the game as the only side in the competition yet to score, and in the fifth minute they looked to have found the breakthrough but Thijs Dallinga’s effort was disallowed for offside. Lille thought they had found a way through but Alexsandro’s header from a corner came crashing back off the upright. The visitors had another chance when Matias Fernandez-Pardo skipped through the Bologna defence but keeper Lukasz Skorupski was quick off his line to stop him getting his shot away. Lille did not have long to wait, however, and the goal came from poor Bologna defending. Stefan Posch’s attempted clearance came back off teammate Sam Beukema and Jonathan David was quickest to react and pull the ball back for Mukau. He had time to settle himself for the strike and when Charalampos Lykogiannis blocked the goalbound effort, Mukau made no mistake at the second attempt. Fernandez-Pardo had another chance to get the better of Skorupski, but again the Bologna keeper got down to snatch the ball away as the Lille forward attempted to take it past him. Dallinga had a header saved by Lille keeper Lucas Chevalier but Bologna could finally celebrate when Lykogiannis floated a free kick into the box and Lucumi got ahead of everyone to poke the ball in at the near post. Elation turned to heartbreak for Bologna when Fernandez-Pardo was allowed make his way into the area yet again and this time he pulled the ball back for the unmarked Mukau who steered his shot in from close range. (Reporting by Trevor Stynes, editing by Ed Osmond) Disclaimer: This report is auto generated from the Reuters news service. ThePrint holds no responsibilty for its content. var ytflag = 0;var myListener = function() {document.removeEventListener('mousemove', myListener, false);lazyloadmyframes();};document.addEventListener('mousemove', myListener, false);window.addEventListener('scroll', function() {if (ytflag == 0) {lazyloadmyframes();ytflag = 1;}});function lazyloadmyframes() {var ytv = document.getElementsByClassName("klazyiframe");for (var i = 0; i < ytv.length; i++) {ytv[i].src = ytv[i].getAttribute('data-src');}} Save my name, email, and website in this browser for the next time I comment. Δ document.getElementById( "ak_js_1" ).setAttribute( "value", ( new Date() ).getTime() );

(The Center Square) – Legislators in Washington, D.C., have taken a number of steps over the past few days to push for insurance and pharmaceutical reforms to be passed before the end of the year. On Wednesday, a bicameral group of Republican and Democrat lawmakers held a press conference discussing the need for pharmacy benefit manager reform to protect small pharmacies across the country and “save lives.” “Whether you are a Republican, Democrat, or an independent, we all want the same thing. We want accessible, affordable, quality health care,” said Rep. Buddy Carter, R-Ga. “We’re not here today to just discuss one bill or to discuss just one patient’s story. We're here because there's broad, bipartisan pharmacy benefit manager, or PBM, reform that is needed to save lives.” Pharmacy benefit managers are the middlemen responsible for managing the drug prices covered by health insurance plans. According to the Harvard Political Review , the problem with pharmacy benefit managers is that they “have vertically integrated with pharmacy chains and health insurers through massive conglomerates.” That then allows them to abuse their power to cut out small pharmacies and increase prices. Carter also signed a letter that was released last week calling on the Department of Justice to dig into the role pharmacy benefit managers played in the opioid epidemic. Reps. Raja Krishnamoorthi, D-Ill., Deborah Ross, D-N.C., and Cliff Benz, R-Ore., all joined him in signing that letter. “The opioid crisis has devastated communities in North Carolina and across the country, and PBMs may have fueled it by prioritizing profits over people,” Ross said on social media . “That’s why I joined a letter calling on the DOJ to investigate their role and hold these bad actors accountable.” The letter looked at recent reports on the largest pharmacy benefit managers, CVS Caremark, Express Scripts, and OptumRx which state that they “colluded and conspired to steer patients towards OxyContin in exchange for $400 million.” OxyContin is a trade name for the narcotic oxycodone hydrochloride, a painkiller available by prescription only. This and the general “lack of transparency” is just one of the many complaints that legislators aired on Wednesday. “My colleagues who are joining me today, Democrats and Republicans ... all recognize that PBMs are decreasing the accessibility, the affordability, and therefore the quality of health care in America,” Carter said. “We have an opportunity, right now, to advance bipartisan legislation that increases reporting requirements, which would heighten transparency and shine a light on the opaque practices of these PBMs.” Carter was also joined by Sen. James Lankford, R-Okla., who is leading the effort to get legislation passed in the U.S. Senate. “This year, we're losing about one pharmacy a day in America,” Lankford said. “We want leadership to be able to take this up and to bring it up in the end-of-year package ... Stop holding up legislation that is bipartisan, bicameral, and solving a problem that Americans need solved.”

Milliman analysis: Competitive pension risk transfer costs decrease from 101.7% to 101.2% during October

None